3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Carboplatin
49
Pemetrexed
38
Cisplatin
34
Radiotherapy
32
Docetaxel
31
Gemcitabine
25
Paclitaxel
24
Nivolumab
18
pembrolizumab
15
Etoposide
15
Radiosurgery
13
Erlotinib Hydrochloride
11
Bevacizumab
11
Magnetic Resonance Spectroscopy
10
Vinorelbine
9
Radiation
9
Cyclophosphamide
7
Gefitinib
6
Fluorodeoxyglucose F18
6
Celecoxib
6
durvalumab
5
atezolizumab
5
Oxaliplatin
5
Irinotecan
5
Immunoglobulin G
5
Drug Therapy
5
Disulfides
5
Dexamethasone
5
Chemotherapy, Adjuvant
5
vandetanib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lung Neoplasms
×
trilaciclib
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts